肺部液體霧化給藥器是上海玉研儀器專門(mén)為小鼠、大鼠、豚鼠等小動(dòng)物研發(fā)設(shè)計(jì)，可精確對(duì)氣管內(nèi)進(jìn)行霧化給藥的裝置。可將定量液體通過(guò)集成在不銹鋼毛細(xì)插管中的氣溶膠霧化微噴頭霧化，毛細(xì)插管可深入動(dòng)物至支氣管分叉處，實(shí)現(xiàn)氣管內(nèi)定量霧化成氣溶膠給藥。相較于傳統(tǒng)口服或注射給藥，藥物可直接作用于肺部，適用于肺部生理、病理、藥理學(xué)研究。

優(yōu)勢(shì)特點(diǎn)：

1.適用于小鼠、大鼠、豚鼠、兔子等小動(dòng)物，也可定制大動(dòng)物款
2.氣管內(nèi)直接給藥，無(wú)首關(guān)消除，藥物全身效應(yīng)小
3.微量精確給藥，藥物用量可達(dá)25μL（液體）
4.可用于溶液、小細(xì)胞懸浮液、均質(zhì)懸濁液、粘度較低的乳濁液
5.90%藥物霧化直徑≤30μm（液體），可達(dá)終末細(xì)支氣管甚至呼吸性細(xì)支氣管，可均勻分布于大小鼠肺部組織中
6.使用方便，安全穩(wěn)定，采用不銹鋼材質(zhì)，堅(jiān)固穩(wěn)定耐腐蝕
7.具有至少30篇高影響因子SCI文獻(xiàn)發(fā)表，可提供至少1篇IF大于35分的SCI文獻(xiàn)
8.設(shè)備具有CE認(rèn)證證書(shū)或EC符合性證書(shū)
9.可用于吸入毒理學(xué)、空氣生物學(xué)、生物危害測(cè)試、吸入免疫、吸入治*、藥物研究、環(huán)境評(píng)價(jià)、危害評(píng)估和醫(yī)學(xué)防護(hù)等多領(lǐng)域

應(yīng)用領(lǐng)域：

1. 研究肺部吸收機(jī)制：通過(guò)給予標(biāo)記的藥物,可以觀察藥物在肺泡和肺間質(zhì)中的吸收和轉(zhuǎn)運(yùn)過(guò)程，也可以準(zhǔn)確測(cè)定藥物在肺泡、肺間質(zhì)等不同部位的吸收速率和吸收程度，從而建立可靠的藥物吸收模型。

2. 分析肺部代謝過(guò)程 :使用肺部給藥技術(shù),可以檢測(cè)給藥后藥物在肺內(nèi)代謝產(chǎn)物的形成和變化，幫助分析肺部代謝酶的活性和代謝途徑，也可以分析藥物在肺內(nèi)的代謝動(dòng)力學(xué)，包括代謝速率、代謝產(chǎn)物的形成和清理。

3. 評(píng)估肺部清理機(jī)制：肺部給藥可作用于肺部，研究肺泡巨噬細(xì)胞、肺表面活性物質(zhì)、纖毛運(yùn)動(dòng)等對(duì)藥物清理的影響。

4. 探索肺部免疫反應(yīng)和屏障功能：通過(guò)肺部給予免疫刺激藥物，可以觀察肺部免疫細(xì)胞的激*和炎癥反應(yīng)。使用標(biāo)記的粒子或大分子作為探針，可以評(píng)估肺血管內(nèi)皮、上皮等屏障結(jié)構(gòu)對(duì)物質(zhì)通透性的調(diào)控作用。

5.建立肺部-全身循環(huán)的藥動(dòng)學(xué)模型：通過(guò)肺部給藥數(shù)據(jù)，可以建立詳細(xì)的肺部-血漿-全身循環(huán)的藥動(dòng)學(xué)模型，更準(zhǔn)確地預(yù)測(cè)藥物在體內(nèi)的吸收、分布、代謝和清理過(guò)程。

氣管內(nèi)給藥示意圖

肺纖維化大小鼠模型

傳統(tǒng)經(jīng)典的復(fù)制肺纖維化大小鼠模型方法是通過(guò)氣管內(nèi)滴入博萊霉素溶液，其主要方式有兩種：有創(chuàng)氣管切開(kāi)滴注以及無(wú)創(chuàng)經(jīng)口氣管滴注。有創(chuàng)氣管切開(kāi)滴注會(huì)對(duì)實(shí)驗(yàn)動(dòng)物造成外源性損傷，增加了實(shí)驗(yàn)動(dòng)物失血過(guò)多和感*的風(fēng)險(xiǎn)，無(wú)創(chuàng)經(jīng)口氣管滴注可引起明顯的肺組織損傷與肺纖維化改變，但溶液呈液滴狀進(jìn)入肺內(nèi)，其液滴相對(duì)較大，藥物較集中，容易造成動(dòng)物窒息死亡。

無(wú)創(chuàng)經(jīng)口氣管內(nèi)霧化給藥則是一種更新、更有效的促進(jìn)藥物肺內(nèi)均勻分布的方法，可以將博萊霉素溶液分散為體積更小的液滴，在氣流的推動(dòng)下，分散的液滴能進(jìn)入各肺葉，并可到達(dá)外周肺組織，因此造成累及各肺葉、出現(xiàn)程度相近的纖維化改變、范圍更彌散的肺組織損傷，更接近人類肺纖維化改變。氣管內(nèi)霧化博萊霉素溶液對(duì)小鼠的創(chuàng)傷小，很少出現(xiàn)窒息的情況，且不需穿刺氣管，減少了動(dòng)物的損傷與痛苦，降低了實(shí)驗(yàn)鼠的死亡率，并且藥物劑量可以準(zhǔn)確控制，實(shí)驗(yàn)結(jié)果重復(fù)性好，可作為復(fù)制肺纖維化大小鼠模型的良好方案。

由于大小鼠肺部疾病模型造模指向性強(qiáng)，需要直接將造模藥物均勻輸送到肺組織中。因此包括哮喘模型，肺纖維化模型，急性肺組織損傷模型，病毒感*模型等肺部疾病模型均可使用經(jīng)口氣管內(nèi)霧化給藥造模。

相關(guān)產(chǎn)品推薦：

合適的工具能幫助您更好地完成工作，氣管插管臺(tái)和小動(dòng)物喉鏡是幫助您完成肺部給藥手術(shù)的得力助手，推薦與肺部干粉霧化給藥器配合使用。

氣管插管平臺(tái)

氣管插管平臺(tái)支持小鼠、大鼠等小動(dòng)物在一個(gè)穩(wěn)定舒適的方位開(kāi)展氣管插管、藥物灌注及其它類似實(shí)驗(yàn)操作?？梢愿鶕?jù)需要進(jìn)行不同孔位的固定，進(jìn)行多種操作角度的調(diào)節(jié)，滿足不同實(shí)驗(yàn)類型以及實(shí)驗(yàn)動(dòng)物種類的需求。雙面操作模式，使得肺部給藥操作更為流暢順利，可與我公司小動(dòng)物呼吸機(jī)、麻醉機(jī)、肺部定量給藥器、喉鏡等配合使用，也可根據(jù)要求進(jìn)行定制。

CG-02型

CG-02型

CG-06型

小動(dòng)物喉鏡

SR310型小動(dòng)物喉鏡，用于觀察實(shí)驗(yàn)動(dòng)物的喉部等結(jié)構(gòu)，以進(jìn)行肺部給藥、經(jīng)口氣管插管等操作，適用于小鼠、大鼠、豚鼠，也可根據(jù)您的要求進(jìn)行定制。采用光纖LED照明系統(tǒng)，提供清晰明亮的光線，給觀察喉部、會(huì)厭等結(jié)構(gòu)的操作人員提供了更好的視野。前端為不銹鋼的葉型尖部，可隨時(shí)拆卸或更換。操作柄的形狀符合人體工程學(xué)，使操作更舒適方便。

產(chǎn)品特點(diǎn)：

1.外殼采用金屬材質(zhì)，堅(jiān)固耐用，易清洗                    

2.操作柄的形狀符合人體工程學(xué)的原理，手握舒適 

3.專為大小鼠口腔結(jié)構(gòu)設(shè)計(jì)的特制葉片，解決了因口腔太小難以插管的難題 

4.具有大鼠葉片和小鼠葉片供選擇 

5.葉片采用不銹鋼材質(zhì)，很大限度地減少腐蝕，確保耐用 

6.電池采用兩節(jié)5號(hào)電池，方便更換

大小鼠進(jìn)口光纖葉片

部分用戶名單：

參考文獻(xiàn)：

1.Zhu, Chuanda, et al. "An elastase nanocomplex with metal cofactors for enhancement of target protein cleavage activity and synergistic antitumor effect." Chemical Engineering Journal (2024): 149902.doi:10.1016/j.cej.2024.149902.
2.Zhu, Chuanda, et al. "An elastase nanocomplex with metal cofactors for enhancement of target protein cleavage activity and synergistic antitumor effect." Chemical Engineering Journal (2024): 149902，doi:10.1016/j.cej.2024.149902
3.Sun, Xiaolin et al. “GSTP alleviates acute lung injury by S-glutathionylation of KEAP1 and subsequent activation of NRF2 pathway.” Redox biology vol. 71 (2024): 103116. doi:10.1016/j.redox.2024.103116
4.Han, Meng-Meng et al. “Inhaled nanoparticles for treating idiopathic pulmonary fibrosis by inhibiting honeycomb cyst and alveoli interstitium remodeling.” Journal of controlled release : official journal of the Controlled Release Society vol. 366 (2024): 732-745. doi:10.1016/j.jconrel.2024.01.032
5.Feng, Xin et al. “First magnetic particle imaging to assess pulmonary vascular leakage in vivo in the acutely injured and fibrotic lung.” Bioengineering & translational medicine vol. 9,2 e10626. 29 Nov. 2023, doi:10.1002/btm2.10626
6.Fan, Weiyang et al. “Naringenin regulates cigarette smoke extract-induced extracellular vesicles from alveolar macrophage to attenuate the mouse lung epithelial ferroptosis through activating EV miR-23a-3p/ACSL4 axis.” Phytomedicine : international journal of phytotherapy and phytopharmacology vol. 124 (2024): 155256. doi:10.1016/j.phymed.2023.155256
7.Li, Cheng et al. “Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.” Cell vol. 185,8 (2022): 1389-1401.e18. doi:10.1016/j.cell.2022.03.009
8.Liu, Chang et al. “An Inhalable Hybrid Biomimetic Nanoplatform for Sequential Drug Release and Remodeling Lung Immune Homeostasis in Acute Lung Injury Treatment.” ACS nano vol. 17,12 (2023): 11626-11644. doi:10.1021/acsnano.3c02075
9.Peng, Boya et al. “Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy.” Journal of extracellular vesicles vol. 11,4 (2022): e12187. doi:10.1002/jev2.12187
10.Yang, Guang, et al. "Noncovalent co-assembly of aminoglycoside antibiotics@ tannic acid nanoparticles for off-the-shelf treatment of pulmonary and cutaneous infections." Chemical Engineering Journal 474 (2023): 145703.do:10.1016/j.cej.2023.145703.
11.Santin, Yohan et al. “Inhalation of acidic nanoparticles prevents doxorubicin cardiotoxicity through improvement of lysosomal function.” Theranostics vol. 13,15 5435-5451. 2 Oct. 2023, doi:10.7150/thno.86310
12.Sun, Han et al. “Application of Lung-Targeted Lipid Nanoparticle-delivered mRNA of soluble PD-L1 via SORT Technology in Acute Respiratory Distress Syndrome.” Theranostics vol. 13,14 4974-4992. 4 Sep. 2023, doi:10.7150/thno.86466
13.Yue, Dayong et al. “Diesel exhaust PM2.5 greatly deteriorates fibrosis process in pre-existing pulmonary fibrosis via ferroptosis.” Environment international vol. 171 (2023): 107706. doi:10.1016/j.envint.2022.107706
14.Zhang, Mengjun et al. “Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment.” Journal of controlled release : official journal of the Controlled Release Society vol. 352 (2022): 422-437. doi:10.1016/j.jconrel.2022.10.020
15.Gu, Peiyu et al. “Protective function of interleukin-22 in pulmonary fibrosis.” Clinical and translational medicine vol. 11,8 (2021): e509. doi:10.1002/ctm2.509
16.Wu, Lan et al. “Poly(lactide-co-glycolide) Nanoparticles Mediate Sustained Gene Silencing and Improved Biocompatibility of siRNA Delivery Systems in Mouse Lungs after Pulmonary Administration.” ACS applied materials & interfaces vol. 13,3 (2021): 3722-3737. doi:10.1021/acsami.0c21259
17.Tian, Xidong et al. “Pulmonary Delivery of Reactive Oxygen Species/Glutathione-Responsive Paclitaxel Dimeric Nanoparticles Improved Therapeutic Indices against Metastatic Lung Cancer.” ACS applied materials & interfaces vol. 13,48 (2021): 56858-56872. doi:10.1021/acsami.1c16351
18.Lin, Wei-Ting et al. “Modulation of experimental acute lung injury by exosomal miR-7704 from mesenchymal stromal cells acts through M2 macrophage polarization.” Molecular therapy. Nucleic acids vol. 35,1 102102. 14 Dec. 2023, doi:10.1016/j.omtn.2023.102102
19.Yang, Huilin et al. “Triptolide dose-dependently improves LPS-induced alveolar hypercoagulation and fibrinolysis inhibition through NF-κB inactivation in ARDS mice.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 139 (2021): 111569. doi:10.1016/j.biopha.2021.111569
20.Feng, Xin et al. “First magnetic particle imaging to assess pulmonary vascular leakage in vivo in the acutely injured and fibrotic lung.” Bioengineering & translational medicine vol. 9,2 e10626. 29 Nov. 2023, doi:10.1002/btm2.10626
21.Xiao, Xue et al. “SerpinB1 is required for Rev-erbα-mediated protection against acute lung injury induced by lipopolysaccharide-in mice.” British journal of pharmacology vol. 180,24 (2023): 3234-3253. doi:10.1111/bph.16175
22.Su, Ruonan et al. “Venetoclax nanomedicine alleviates acute lung injury via increasing neutrophil apoptosis.” Biomaterials science vol. 9,13 (2021): 4746-4754. doi:10.1039/d1bm00481f
23.Xu, Yingying et al. “PEGylated pH-responsive peptide-mRNA nano self-assemblies enhance the pulmonary delivery efficiency and safety of aerosolized mRNA.” Drug delivery vol. 30,1 (2023): 2219870. doi:10.1080/10717544.2023.2219870
24.Wu, Yanqi et al. “SN50 attenuates alveolar hypercoagulation and fibrinolysis inhibition in acute respiratory distress syndrome mice through inhibiting NF-κB p65 translocation.” Respiratory research vol. 21,1 130. 27 May. 2020, doi:10.1186/s12931-020-01372-6
25.Chen, Huanjie et al. “Enhanced secretion of hepatocyte growth factor in human umbilical cord mesenchymal stem cells ameliorates pulmonary fibrosis induced by bleomycin in rats.” Frontiers in pharmacology vol. 13 1070736. 6 Jan. 2023, doi:10.3389/fphar.2022.1070736